CEVR faculty and researchers will present on numerous topics at ISPOR 2024 in Atlanta, including sessions on the IRA, Alzheimer’s disease, and novel value assessment:
Monday, May 6
- Forums
- 11:45 am – 12:45 pm. Unlocking the Potential of Open-Source Models: Strategies to Navigate Barriers in Development and Adoption
- Moderator: Renée JG Arnold, PharmD, RPh, National Institutes of Health/NHLBI and BioHealth Innovation, Inc.
- Speakers: Daniel Ollendorf, PhD, Institute for Clinical and Economic Review, Tufts Medical Center (CEVR); Rob M. Boer, PhD, AbbVie; Elisabeth Anne Louise Fenwick, PhD, OPEN Health Communications
- 11:45 am – 12:45 pm. Unlocking the Potential of Open-Source Models: Strategies to Navigate Barriers in Development and Adoption
- Student Network Roundtable
- 1:30 pm – 2:30 PM. Unpacking the Inflation Reduction Act (IRA): Status and Implications Beyond Drug Pricing
- Moderator: Jordan M Skiera, PharmD/MSL Candidate of 2025, Samford University McWhorter School of Pharmacy
- Speakers: Christoph Glaetzer, Dipl. Kfm, Johnson & Johnson; T. Joseph Mattingly, PharmD, MBA, PhD, Department of Pharmacotherapy, University of Utah College of Pharmacy; Julie Patterson, PharmD, PhD, National Pharmaceutical Council; Peter Neumann, ScD Tufts Medical Center (CEVR)
- 1:30 pm – 2:30 PM. Unpacking the Inflation Reduction Act (IRA): Status and Implications Beyond Drug Pricing
- Events
- 4:15 pm – 5:15 pm, Room A404, Georgia World Congress Center, Building A. Hosting the ISPOR Boston Chapter Event
- If you’re in the Boston chapter, come by and say “hello”!
- 4:15 pm – 5:15 pm, Room A404, Georgia World Congress Center, Building A. Hosting the ISPOR Boston Chapter Event
- Poster Session 1
- The Health Equity Impact of a Hypothetical Disease-Modifying Treatment for Alzheimer's Disease in the United States: A Distributional Cost-Effectiveness Analysis
- Synnott P, Lin PJ, Ollendorf D, Zhu Y, Majda T, Kowal S
- Value of Knowing Risk of Developing Neurodegenerative Disease: A Discrete Choice Experiment
- Crummer E, Synnott P, Vera-Llonch M, Kymes S, Ollendorf D
- What Is the Impact of Including Outcomes-Based Agreements on the Cost-Effectiveness of Cell and Gene Therapies? A Case Example of Zynteglo for Transfusion-Dependent Beta Thalassemia
- Richardson M, Beaudoin F, Rind DM, Synnott P, Herce-Hagiwara B, Ollendorf D
- Estimating a Drug's Price After Loss of Exclusivity as a Function of the Cost of Goods Sold
- Whittington M, Mattingly TJ
- Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Longitudinal Study Using the EQ5D and Health Utilities Index (HUI)
- Szabo SM, Audhya IF, Bever A, Sun R, Griffin E, Feeny D, Malone D, Neumann P, Iannaccone ST, Gooch KL
- The Health Equity Impact of a Hypothetical Disease-Modifying Treatment for Alzheimer's Disease in the United States: A Distributional Cost-Effectiveness Analysis
- Poster Session 2
- Public Deliberation on Health Gain Measures
- Lin CH, Lavelle T, Phillips M, Riley A, Ollendorf D
- Impact of Slowing Alzheimer’s Disease (AD) Progression: A Simulation Model in a Population of Patients with Early AD in the United States
- Bloudek L, Sullivan S, Sheth S, Elsea D, Kang A, Aly A, Neumann P
- Disparity in New Cancer Drug Launches Worldwide: 1990-2022
- Li M, Ka DH, Chen Q
- Public Deliberation on Health Gain Measures
Tuesday, May 7
- Forums
- 11:45 am – 12:45 pm. Incorporating Health Equity in HTA Systems and Research: A Global Perspective and Future Outlook
- Moderator: Riku Ota, MPH, Novo Nordisk Pharma Ltd.
- Speakers: Ataru Igarashi, Ph.D., Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine; Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR); Jonathan Pearson-Stuttard, FRSPH, FFPH, MAPHA, Health Analytics, Lane Clark & Peacock LLP
- 3:15 pm – 4:15 pm. Uncovering the Impact of HTA on Medical Device and Diagnostic Procurement Process and Outcomes: Insights and Discussion From the ISPOR Medical Devices and Diagnostics SIG Key Project Research
- Moderator: Michael Joseph Cangelosi, MA, MPH, Boston Scientific
- Speakers: Arturo Cabra, MSc, GE Healthcare; Patricia Synnott, MS, MALD, Tufts Medical Center (CEVR); Meike Bomhof, MA, Avania
- 11:45 am – 12:45 pm. Incorporating Health Equity in HTA Systems and Research: A Global Perspective and Future Outlook
- Breakouts
- 10:15 am – 11:15 am. Developing Preference-Based Health-Related Quality-of-Life Instruments for Young Children and Infants: What’s the Best Way to Proceed?
- Moderator: Scott D Grosse, PhD, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention
- Panelists: Tara Lavelle, PhD, Tufts Medical Center (CEVR); Kim Dalziel, PhD, Professor and Head, Health Economics Unit, Centre for Health Policy, The University of Melbourne; Wendy J Ungar, MSc, PhD, Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute
- 1:45 pm – 2:45 pm. I Have a Better QALY Than You: How to Make Sense of Alternatives to the QALY for Research and Policymaking
- Moderator: Daniel Ollendorf, PhD, Institute for Clinical and Economic Review , Tufts Medical Center (CEVR)
- Panelists: Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR), Boston, MA, USA; Darius Lakdawalla, PhD, School of Pharmacy, USC Leonard D. Schaeffer Center for Health Policy and Economics; Anirban Basu, PhD, MS, The CHOICE Institute, University of Washington
- 1:45 pm – 2:45 pm. Revolutionizing Regulatory Pathways: Unleashing the Power of Real-World Evidence, Adaptive Trials, and Synergistic Collaboration for Expedited FDA Device Approval, Breakthrough Designation, and CMS Reimbursement
- Discussion Leader: Renée JG Arnold, PharmD, RPh, NHLBI, National Institutes of Health
- Discussants: Douglas Kelly, MD, Center for Devices & Radiological Health (CDRH), Food and Drug Administration; Steven A. Farmer, MD, PhD, Centers for Medicare & Medicaid Services; Peter Neumann, ScD, Tufts Medical Center (CEVR)
- 5:00 pm – 6:00 pm. Is the Employer Perspective Sufficiently Reflected in Common Value Frameworks?
- Moderator: Katherine T. Lofgren, PhD, MPH, Abett, Inc.
- Panelists: Daniel Ollendorf, PhD, Institute for Clinical and Economic Review, Tufts Medical Center (CEVR); Meng Li, PhD, ScM, Tufts Medical Center (CEVR); Luke Prettol, BA, AT&T, Spring, TX,
- 5:00 pm – 6:00 pm. Actually, Me Too Drugs Are Awesome: Multi-Stakeholder Perspectives on the Value of Me Too Drugs
- Discussion Leader: Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR)
- Discussants: Peter Kolchinsky, PhD, RA Capital Management; Joel C Barrish, PhD, Jnana Therapeutics; Danny Dike, Bachelor of Science, Management Information Systems, Express Scripts
- 10:15 am – 11:15 am. Developing Preference-Based Health-Related Quality-of-Life Instruments for Young Children and Infants: What’s the Best Way to Proceed?
- Symposia
- 11:45 am – 12:45 pm. Methodological and Policy Issues Related to the Cost-Effectiveness of Newborn Screening in Severe Pediatric Genetic Disorders
- Peter Neumann, ScD, Tufts Medical Center (CEVR)
- 1:45 pm – 2:45 pm. Revolutionizing Regulatory Pathways: Unleashing the Power of Real-World Evidence, Adaptive Trials, and Synergistic Collaboration for Expedited FDA Device Approval, Breakthrough Designation, and CMS Reimbursement
- Discussion Leader: Renée JG Arnold, PharmD, RPh, NHLBI, National Institutes of Health, New York, NY, USA
- Discussants: Douglas Kelly, MD, Center for Devices & Radiological Health (CDRH), Food and Drug Administration; Steven A. Farmer, MD, PhD, Centers for Medicare & Medicaid Services; Peter Neumann, ScD, Tufts Medical Center (CEVR)
- 11:45 am – 12:45 pm. Methodological and Policy Issues Related to the Cost-Effectiveness of Newborn Screening in Severe Pediatric Genetic Disorders
- Poster Session 1
- Variation in Commercial Coverage of Accelerated Approval Drugs
- LaMountain F, Beinfeld M, Chambers J
- Variation in Commercial Coverage of Accelerated Approval Drugs
- Poster Session 2
- Economic Burden of Non-Hodgkin Lymphoma Among Patients with Commercial Insurance
- Li M, Liao K, Flowers C
- Variation in Coverage of Specialty Therapies and Barriers to Fair Access
- Beinfeld M, Rucker J, Chambers J
- Economic Burden of Non-Hodgkin Lymphoma Among Patients with Commercial Insurance
Wednesday, May 8
- Breakouts
- 8:00 am – 9:00 am. How Can Grace and Other Novel Methods Estimate ISPOR Value Flower Components? A User Guide to Generalized Cost Effectiveness Analysis (GCEA)
- Discussion Leader: Jason Shafrin, PhD, Center for Healthcare Economics and Policy, FTI Consulting
- Discussants: Lotte Steuten, PhD, Office of Health Economics; Melanie D. Whittington, PhD, MS, Tufts Medical Center (CEVR); Lou Garrison, PhD, The Comparative Health Outcomes, Policy, and Economics Institute, School of Pharmacy, University of Washington
- 10:00 am – 11:00 am. Addressing Key Challenges in the Setting of Tumor-Agnostic Drugs: Meeting an Unmet Need?
- Discussion Leader: Beth Devine, PhD, PharmD, MBA, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA
- Discussants: Emma Mackay, MA, MSc, Inka Health; Yilin Chen, MPH, PhD, Curta, Inc.; Daniel Ollendorf, PhD, Institute for Clinical and Economic Review, Tufts Medical Center (CEVR)
- 8:00 am – 9:00 am. How Can Grace and Other Novel Methods Estimate ISPOR Value Flower Components? A User Guide to Generalized Cost Effectiveness Analysis (GCEA)
- Poster Session
- Do QALYs Discriminate Against the Elderly?
- Zhou T, Humphries B, Neumann P, Xie F
- Do QALYs Discriminate Against the Elderly?